troyal, i am 74 and you sir are an old fart

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Rigel Pharmaceuticals' Business Update and 2025 Outlook Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a notable biotechnology company, recently provided a compelling business update, highlighting its financial performance and strategic ambitions for 2025. The report shared preliminary insights into the fourth quarter of 2024, showcasing substantial revenue streams from its...

Understanding Investment Shifts in Today's Economy Grant Cardone, a prominent real estate investor and entrepreneur known for his work with Cardone Capital, is keeping a keen eye on the fluctuations within the investment landscape. With approximately $7 trillion currently held in money markets, he questions where this substantial amount of cash will be allocated as...

BlueNord ASA Successfully Places Hybrid Bond Issue BlueNord ASA (OSE: BNOR) has achieved a significant milestone in its financial strategy with the successful placement of a new subordinated callable hybrid bond issue worth USD 300 million. This bond matures in 2085, marking a robust step forward for the company. The first call on the hybrid bond is at 100% of nominal...

Strong Start to 2026 for Aehr Test Systems For shares of Aehr Test Systems, the year 2026 has kicked off in a remarkable way. As of the latest market close, the stock has risen by 44%, showcasing significant investor enthusiasm. This surge follows a recent earnings release that, while presenting mixed signals, ultimately contributed to a 16% jump in the stock price the...

Carlton Precious Inc. Strengthens Community Engagement TORONTO — Carlton Precious Inc. (TSX-V: CPI | OTCQB: NBRFF), a notable player in precious and base metals exploration, is excited to share significant developments regarding its Esquilache Silver project. The Company has successfully finalized an agreement with the local community of San Antonio de Esquilache, which...